Samsca Tablet
Product Images NDC 59148-020

6 FDA label images from Otsuka America Pharmaceutical, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Samsca (NDC 59148-020). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Otsuka America Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Samsca Chem Structure)

Chemical Structure (Samsca Chem Structure)
Chemical structure of tolvaptan, the active ingredient in SAMSCA tablets. The diagram shows tolvaptan's molecular framework with labeled rings and functional groups relevant to its chemical composition.*
FDA Label Image

Figure 1 (Samsca Figure 01)

Figure 1 (Samsca Figure 01)
A line graph depicting mean serum sodium levels (mEq/L) with standard deviation over treatment days for Tolvaptan 15-60 mg versus placebo. The x-axis shows baseline, hours within day 1, days 3 to 30, and 7-day follow-up. Tolvaptan shows a higher mean serum sodium increase compared to placebo, with statistically significant differences marked.*
FDA Label Image

Figure 2 (Samsca Figure 02)

Figure 2 (Samsca Figure 02)
Line graph comparing mean serum sodium levels (mEq/L) over treatment days between tolvaptan 15-60 mg and placebo groups. The graph shows increasing sodium levels in the tolvaptan group, remaining higher than placebo across days 1 to 30, with markers indicating statistical significance versus placebo. A 7-day follow-up sodium level is also plotted for tolvaptan.*
FDA Label Image

Figure 3 (Samsca Figure 03)

Figure 3 (Samsca Figure 03)
A line graph depicting mean serum sodium levels (mEq/L) with standard deviation over time from baseline through week 50, for patients treated with Tolvaptan 15-60 mg (N=111). The x-axis represents time in weeks, and significant changes from baseline are marked with asterisks. The graph shows an initial rise in serum sodium levels, which then stabilize with slight fluctuations over the study period.*
FDA Label Image

Principal Display Panel (15 mg Tablet Blister Pack Carton)

Principal Display Panel (15 mg Tablet Blister Pack Carton)
Samsca (tolvaptan) tablets 15 mg oral tablet packaging label from Otsuka America Pharmaceutical, Inc. The label indicates a carton of 10 tablets, must be initiated in hospital, and includes dispensing instructions for a medication guide. The label also provides storage instructions and manufacturer information from Otsuka Pharmaceutical Co., Ltd., Japan.*
FDA Label Image

Principal Display Panel (30 mg Tablet Blister Pack Carton)

Principal Display Panel (30 mg Tablet Blister Pack Carton)
Samsca (tolvaptan) tablets 30 mg oral tablet packaging label. The carton contains 10 tablets and is labeled for prescription use only. Manufactured by Otsuka Pharmaceutical Co., Ltd. and distributed by Otsuka America Pharmaceutical, Inc. Storage instructions specify 25°C with permitted excursions. The label includes a drug guide warning and barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.